Contract testing laboratories now have access to a revolutionary tool: the FDA-cleared EUROIMMUN chemiluminescence immunoassay (ChLIA) for free testosterone. This innovative test simplifies diagnostic workflows and delivers accurate results, ensuring labs can meet the rising demand for precision testing.
Why Contract Labs Benefit from This Testosterone Assay
- Unmatched speed: First result ready in 48 minutes; handles up to 60 tests per hour.
- Enhanced accuracy: Monoclonal antibodies provide batch-to-batch consistency and specificity.
- Streamlined operations: Compatible with iSYSTM and i10TM platforms for random-access testing.
- Comprehensive diagnostics: Essential for assessing androgen disorders like PCOS and hypogonadism.
By reducing technician training requirements and accelerating test turnaround times, this assay empowers contract labs to deliver results that meet high standards of reliability and accuracy.
Jonathan Friend of EUROIMMUN US remarks: “This clearance reinforces our commitment to expanding the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions with assays that serve diverse patient populations across all demographics.”
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: “Revvity Announces FDA Clearance for First Automated Free Testosterone Test“
